Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.64 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 3/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28800255 | 1.00 | GSR (0.64) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL221848 | 0.93 | — | — | |
| SCHEMBL9915164 | 0.80 | GSR (0.70) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL27135893 | 0.79 | GSR (0.80) | GSRRNPEPCPB2ARG1ARG2 | |
| SCHEMBL363001 | 0.78 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL12867528 | 0.78 | GSR (1.00) | GSRRNPEPCPB2ARG1ARG2 | |
| SCHEMBL1129351 | 0.78 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| SCHEMBL5498760 | 0.78 | GSR (0.67) | GSRRNPEPGNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL8613373 | 0.78 | GSR (1.00) | GSRRNPEPCPB2ARG1ARG2 | |
| Lysine SCHEMBL20362357 | 0.78 | GSR (1.00) | GSRRNPEPCPB2ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4015526-B1 | RECOMBINANT INTERLEUKIN-15 ANALOG | LETO LABORATORIES CO LTD (CN) | 2024-10-30 | — | — | EP | claimed |
| CN-112552391-B | Recombinant interleukin-15 analogue | 北京志道生物科技有限公司 | 2024-08-23 | — | — | CN | claimed |
| CN-117362411-A | Interleukin 15 protein mutant and application thereof | 北京志道生物科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20220348624-A1 | RECOMBINANT INTERLEUKIN-15 ANALOG | LETO LABORATORIES CO., LTD (CN) | 2022-11-03 | — | — | US | claimed |
| EP-4015526-A1 | RECOMBINANT INTERLEUKIN-15 ANALOG | Leto Laboratories Co., Ltd (CN) | 2022-06-22 | — | — | EP | claimed |
| EP-4015526-B1 | RECOMBINANT INTERLEUKIN-15 ANALOG | LETO LABORATORIES CO LTD (CN) | 2024-10-30 | — | — | EP | disclosed |
| CN-112552391-B | Recombinant interleukin-15 analogue | 北京志道生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-117362411-A | Interleukin 15 protein mutant and application thereof | 北京志道生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220348624-A1 | RECOMBINANT INTERLEUKIN-15 ANALOG | LETO LABORATORIES CO., LTD (CN) | 2022-11-03 | — | — | US | disclosed |
| CN-114786777-A | RAS inhibitors | 锐新医药公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4015526-A1 | RECOMBINANT INTERLEUKIN-15 ANALOG | Leto Laboratories Co., Ltd (CN) | 2022-06-22 | — | — | EP | disclosed |
| CN-102839497-A | Silk fibroin peptide chain-containing AlaGlyAlaGly polyurethane fiber film and preparation method thereof | UNIV WUHAN TEXTILE | 2012-12-26 | — | — | CN | disclosed |
| US-5523222-A | INJECTING THE POLYAMINO ACID/DNA COMPLEX INTO CYTOPLASM OF ANIMAL CELL IN VITRO | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0704221-A2 | A conjugate useful in gene transfer and a method of producing the same | AJINOMOTO CO., INC. (JP) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994018834-A1 | POLYELECTROLYTE DNA CONJUGATION AND GENETIC TRANSFORMATION OF AN ANIMAL | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 1994-09-01 | — | — | WO | disclosed |